SCHEMBL1759159

SCHEMBL1759159

Cc1ccc(O)c(C(=O)O)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.53
ALDH1A1 P00352 6/20 0.45
KDM4E B2RXH2 5/20 0.45
KMT2A Q03164 2/20 0.42
OPRK1 P41145 1/20 0.42
HPGD P15428 3/20 0.42
MAPT P10636 3/20 0.42
HSD17B10 Q99714 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
RAB9A P51151 2/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42
ALOX15 P16050 1/20 0.42
NFKB1 P19838 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12647208 0.83 GRM5 (0.53) GRM5ALDH1A1KDM4EKMT2AOPRK1
SCHEMBL1405829 0.81 GRM5 (0.40) GRM5ALDH1A1KDM4EKMT2AHPGD
SCHEMBL8695248 0.80 GRM5 (0.47) GRM5ALDH1A1KDM4EKMT2AOPRK1
SCHEMBL2373944 0.80 ALDH1A1 (0.41) GRM5ALDH1A1KDM4EKMT2AOPRK1
SCHEMBL3891217 0.79 GRM5 (0.50) GRM5ALDH1A1KDM4EKMT2AHPGD
SCHEMBL29625359 0.78 GABRP (0.47) ALDH1A1KDM4EKMT2AMAPTSMN1; SMN2
SCHEMBL262422 0.78 GABRP (0.47) ALDH1A1KDM4EKMT2AMAPTSMN1; SMN2
SCHEMBL12664174 0.78 GRM5 (0.49) GRM5ALDH1A1KDM4EKMT2AOPRK1
SCHEMBL12647213 0.78 GRM5 (0.49) GRM5ALDH1A1KDM4EKMT2AOPRK1
SCHEMBL3947679 0.78 GRM5 (0.53) GRM5ALDH1A1KDM4EKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230168-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. 2025-07-17 US disclosed
WO-2025137640-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. (US) 2025-06-26 WO disclosed
WO-2025087274-A1 AZABICYCLO DERIVATIVE AND PREPARATION METHOD THEREFOR, AND USE 浙江海正药业股份有限公司 2025-05-01 WO disclosed
CN-117425657-A Triazolo-pyrimidine analogs for the treatment of diseases associated with inhibition of Wonna syndrome RECzochralski enzyme (WRN) 诺华股份有限公司 2024-01-19 CN disclosed
CN-116782996-A Tautomeric ligands enable biomimetic C-H hydroxylation under molecular oxygen 斯克里普斯研究学院 2023-09-19 CN disclosed
WO-2022125736-A1 A TAUTOMERIC LIGAND ENABLES BIOMIMETIC C-H HYDROXYLATION WITH MOLECULAR OXYGEN THE SCRIPPS RESEARCH INSTITUTE (US) 2022-06-16 WO disclosed
CN-112110853-A Method for synthesizing 3-hydroxy-2-picolinic acid and derivatives thereof 海南梵圣生物科技有限公司 2020-12-22 CN disclosed
EP-2947082-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS Pfizer Inc (US) 2015-11-25 EP disclosed
US-9139587-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2015-09-22 US disclosed
EP-2676958-B1 N1-Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER (US) 2015-07-01 EP disclosed
US-20110111046-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER INC 2011-05-12 US disclosed
EP-1715867-A4 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2009-04-15 EP disclosed
US-20070149547-A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2007-06-28 US disclosed
CN-1933838-A Bipyridyl amides as modulators of metabotropic glutamate receptor-5 MERCK & CO INC (US) 2007-03-21 CN disclosed
US-7183278-B1 Picolinamide derivative and harmful organism control agent comprising said picolinamide derivative as active component MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-27 US disclosed
EP-1715867-A1 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2006-11-02 EP disclosed
WO-2005079802-A1 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2005-09-01 WO disclosed
EP-0981528-A1 REGIOISOMERIC BENZOTHIOPYRANOPYRIDINES HAVING ANTITUMOR ACTIVITY THE UNIVERSITY OF VERMONT (US) 2000-03-01 EP disclosed
WO-1998049172-A1 REGIOISOMERIC BENZOTHIOPYRANOPYRIDINES HAVING ANTITUMOR ACTIVITY UNIVERSITY OF VERMONT (US) 1998-11-05 WO disclosed
US-4089960-A Antiemetic, psychosomatic and antipsychotic heterocyclic pyridine carboxamides CIBA-GEIGY CORPORATION (US) 1978-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230168-A1 AZASPIRO WRN INHIBITORS WRN, RECQL, BLM GRM5 4710/4885ALDH1A1 1316/4885KDM4E 3650/4885
US-20070149547-A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GABRA5 GRM5 1/4885ALDH1A1 1569/4885KDM4E 789/4885
US-20110111046-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB GRM5 3763/4885ALDH1A1 164/4885KDM4E 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.